These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12491132)

  • 21. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?
    Dayer JM; Krane SM
    N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415
    [No Abstract]   [Full Text] [Related]  

  • 23. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M; Favalli EG
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.
    Modesti V; Ramonda R; Ortolan A; Lorenzin M; Lo Nigro A; Frallonardo P; Oliviero F; Campana C; Punzi L
    Scand J Rheumatol; 2012; 41(6):490-1. PubMed ID: 22985209
    [No Abstract]   [Full Text] [Related]  

  • 26. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF; Seipelt E; Zipp F; Paul F
    Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
    [No Abstract]   [Full Text] [Related]  

  • 27. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
    Lehnen M; Goos M; Dissemond J
    Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
    [No Abstract]   [Full Text] [Related]  

  • 28. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
    Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
    [No Abstract]   [Full Text] [Related]  

  • 32. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
    Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
    J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
    Henderson C; Davis JC
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):211-8. PubMed ID: 16932687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J; Baraliakos X; Listing J; Sieper J
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].
    Wendling D; Claudepierre P; Lohse A; Toussirot E; Breban M
    Presse Med; 2003 Oct; 32(32):1517-24. PubMed ID: 14534471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept (Enbrel) -- an update.
    Goffe B
    Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.
    Paul S; Keat A
    Rheumatology (Oxford); 2005 Jan; 44(1):17-23. PubMed ID: 15328421
    [No Abstract]   [Full Text] [Related]  

  • 40. TNF- alpha inhibitors.
    Jackson JM
    Dermatol Ther; 2007; 20(4):251-64. PubMed ID: 17970890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.